Conference News

GLP-1 RAs in Chronic Migraine

Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.

Share

A study presented at the American Academy of Neurology's 78th Annual Meeting found that adults with chronic migraine who initiated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibited fewer emergency department visits, hospitalizations, and escalated preventive therapies compared to those starting topiramate. The study, which analyzed 21,994 patients from the TriNetX database, revealed significant associations with GLP-1 RA treatment but emphasized the need for further randomized controlled trials to establish causation. Key study author Vitoria Acar, MD, noted potential benefits that merit further research.

Original Source(s)

GLP-1 RAs in Chronic Migraine

Investigators evaluate health care utilization and treatment patterns vs topiramate in an active-comparator study.

  • by Kathryn Wighton

  • March 3, 2026

  • 3 min

Related Content

Sleep Apnea’s Billion-Dollar Toll

New analysis links untreated OSA to major productivity losses in working-age adults in the US and UK

Pablo E. Ravenna, M.D., Joins Marcus Neuroscience Institute as a Neuro-ophthalmologist

Neuro-ophthalmologist Pablo E. Ravenna, M.D., has joined Marcus Neuroscience Institute, part of Baptist Health.

  • by

  • February 11, 2026

  • 2 min
COVID Tied to Hidden Smell Deficits

COVID-19 may leave behind unrecognized olfactory deficits linked to cognitive complaints.